Shehzad A Saeed
Biographic Data
| ID | 7692403 |
|---|---|
| NAME | Shehzad A Saeed |
| GIVEN NAMES | Shehzad A |
| FAMILY NAME | Saeed |
| SIGNATURE | SAEED S A |
| AFFILIATIONS | Cincinnati Children's Hospital Medical Center |
| ORCID | 0000-0002-5534-7891 |
| VERIFIED | Yes |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 4 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2014 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Infliximab Biosimilar Utilization in a Large Pediatric Learning Health System
Background/Objectives : Infliximab biosimilars entered the United States (US) market in November 2016. Uptake of infliximab biosimilars has been slow in adult studies. We aimed to assess variation in the initiation of infliximab biosimilars in a large pediatric cohort. Methods : We performed a retrospective cohort study using data from 2016 to 2023 prospectively collected by the ImproveCareNow (ICN) Network, a multicenter pediatric inflammatory b…
Perceived medication adherence barriers mediating effects between gastrointestinal symptoms and health-related quality of life in pediatric inflammatory bowel disease
Gastrointestinal symptoms predictors of health-related quality of life in pediatric patients with functional gastrointestinal disorders
PedsQLTM Gastrointestinal Symptoms Scales and Gastrointestinal Worry Scales in pediatric patients with functional and organic gastrointestinal diseases in comparison to healthy controls
No prominent works on this page.
PedsQLTM Gastrointestinal Symptoms Scales and Gastrointestinal Worry Scales in pediatric patients with functional and organic gastrointestinal diseases in comparison to healthy controls
Gastrointestinal symptoms predictors of health-related quality of life in pediatric patients with functional gastrointestinal disorders
Perceived medication adherence barriers mediating effects between gastrointestinal symptoms and health-related quality of life in pediatric inflammatory bowel disease
Infliximab Biosimilar Utilization in a Large Pediatric Learning Health System
Background/Objectives : Infliximab biosimilars entered the United States (US) market in November 2016. Uptake of infliximab biosimilars has been slow in adult studies. We aimed to assess variation in the initiation of infliximab biosimilars in a large pediatric cohort. Methods : We performed a retrospective cohort study using data from 2016 to 2023 prospectively collected by the ImproveCareNow (ICN) Network, a multicenter pediatric inflammatory b…
Disease (4 works) · Internal Medicine (4 works) · Medicine (4 works) · Child Nutrition and Feeding Issues (3 works) · Quality of life (healthcare (3 works) · Abdominal pain (2 works) · Adolescent and Pediatric Healthcare (2 works) · Bloating (2 works) · Childhood Cancer Survivors' Quality of Life (2 works) · Constipation (2 works)